Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene

Cancer Letters

Volumn 157, Issue 1, 2000, Pages 105-112

  Inoue, Akira ^a   Narumi, Koh ^a   Matsubara, Nobumichi ^a   Sugawara, Shun Ichi ^a   Saijo, Yasuo ^a   Satoh, Ken ^a   Nukiwa, Toshihiro ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Adenoviral vector; Anti cancer agents; Lung cancer cell lines; p53; Synergistic effect

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; GENE; GENE TRANSFER; HUMAN; HUMAN CELL; LUNG CANCER; MUTANT; PRIORITY JOURNAL;

ADENOVIRUSES, HUMAN; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; G1 PHASE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 0034739331     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00480-8     Document Type: Article

References (32)

1. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature. 351:1991;453-456.
2. Harris C.C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88:1996;1442-1455.
3. Johnson B.E. Molecular biology of lung cancer. Mendelsohn J., Howley P.M., Israel M.A., Liotta L.A. The Molecular Basis of Cancer. 1st ed. 1995;317-339 W.B. Saunders, Philadelphia, PA.
4. DeVita J.V.T. Principles of cancer management: chemotherapy. DeVita J.V.T., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. 5th ed. 1997;333-348.
5. Beck W.T., Dalton W.S. Mechanisms of drug resistance. DeVita J.V.T., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. 5th ed. 1997;498-512.
6. Fujiwara T., Grimm E.A., Mukhopadhyay T., Zhang W.W., Owen-Schaub L.B., Roth J.A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54:1994;2287-2291.
7. Gjerset R.A., Turla S.T., Sobol R.E., Scalise J.J., Mercola D., Collins H., Hopkins P.J. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol. Carcinog. 14:1995;275-285.
8. Xu G.W., Sun Z.T., Forrester K., Wang X.W., Coursen J., Harris C.C. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology. 24:1996;1264-1268.
9. Blagosklonny M.V., El-Deiry W.S. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int. J. Cancer. 75:1998;933-940.
10. Nemunaitis J., Swisher S.G., Timmons T., Connors D., Mack M., Doerksen L., Weill D., Wait J., Lawrence D.D., Kemp B.L., Fossella F., Glisson B.S., Hong W.K., Khuri F.R., Kurie J.M., Lee J.J., Lee J.S., Nguyen D.M., Nesbitt J.C., Perez-Soler R., Pisters K.M., Putnam J.B., Richli W.R., Shin D.M., Walsh G.L., Merritt J., Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 18:2000;609-622.
11. Chen J.Y., Funk W.D., Wright W.E., Shay J.W., Minna J.D. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene. 8:1993;2159-2166.
12. Jia L.Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T. Screening the p53 status of human cell lines using a yeast functional assay. Mol. Carcinog. 19:1997;243-253.
13. Noble J.R., Willetts K.E., Mercer W.E., Reddel R.R. Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Exp. Cell Res. 203:1992;297-304.
14. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:1977;59-74.
15. Narumi K., Suzuki M., Song W., Moore M.A., Crystal R.G. Intermittent, repetitive corticosteroid-induced upregulation of platelet levels after adenovirus-mediated transfer to the liver of a chimeric glucocorticoid-responsive promoter controlling the thrombopoietin cDNA. Blood. 92:1998;822-833.
16. Korst R.J., Bewig B., Crystal R.G. In vitro and in vivo transfer and expression of human surfactant SP-A- and SP-B-associated protein cDNAs mediated by replication-deficient, recombinant adenoviral vectors. Hum. Gene Ther. 6:1995;277-287.
17. Boshart M., Weber F., Jahn G., Dorsch-Hasler K., Fleckenstein B., Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell. 41:1985;521-530.
18. McGrory W.J., Bautista D.S., Graham F.L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology. 163:1988;614-617.
19. Berenbaum M.C. Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res. 35:1981;269-335.
20. Larsen J.K., Munch-Petersen B., Christiansen J., Jorgensen K. Flow cytometric discrimination of mitotic cells: resolution of M, as well as G1, S, and G2 phase nuclei with mithramycin, propidium iodide, and ethidium bromide after fixation with formaldehyde. Cytometry. 7:1986;54-63.
21. Takahashi T., Carbone D., Nau M.M., Hida T., Linnoila I., Ueda R., Minna J.D. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 52:1992;2340-2343.
22. Zhang W.W., Fang X., Mazur W., French B.A., Georges R.N., Roth J.A. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1:1994;5-13.
23. Fujiwara T., Grimm E.A., Mukhopadhyay T., Cai D.W., Owen-Schaub L.B., Roth J.A. retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 53:1993;4129-4133.
24. Qazilbash M.H., Xiao X., Seth P., Cowan K.H., Walsh C.E. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther. 4:1997;675-682.
25. Kanamori Y., Kigawa J., Minagawa Y., Irie T., Oishi T., Shimada M., Takahashi M., Nakamura T., Sato K., Terakawa N. newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53- deleted ovarian cancer cells. Eur. J. Cancer. 34:1998;1802-1806.
26. Yang B., Eshleman J.R., Berger N.A., Markowitz S.D. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin. Cancer Res. 2:1996;1649-1657.
27. Blagosklonny M.V., el-Deiry W.S. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int. J. Cancer. 67:1996;386-392.
28. Nielsen L.L., Lipari P., Dell J., Gurnani M., Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 4:1998;835-846.
29. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S., Fornace A.J. Jr., Kohn K.W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57:1997;4285-4300.
30. Cajot J.F., Anderson M.J., Lehman T.A., Shapiro H., Briggs A.A., Stanbridge E.J. Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild-type p53 protein. Cancer Res. 52:1992;6956-6960.
31. Clayman G.L., el-Naggar A.K., Lippman S.M., Henderson Y.C., Frederick M., Merritt J.A., Zumstein L.A., Timmons T.M., Liu T.J., Ginsberg L., Roth J.A., Hong W.K., Bruso P., Goepfert H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16:1998;2221-2232.
32. Chabner B.A., Allegra C.J., Curt G.A., Calabresi P. Antineoplastic agents. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed. 1996;1233-1287 McGraw-Hill, New York.